Escalation of liPid-lOwering therapy in patientS wiTh vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study

Abstract In this retrospective study, we investigated whether lipid-lowering therapy (LLT) escalation has clinical benefits in patients with atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol (LDL-C) levels of 55–99 mg/dL (1.4–2.6 mmol/L), post high-intensity. Out...

Full description

Bibliographic Details
Main Authors: Jaehyung Ha, Bom Lee, Jung Mi Park, Moonjong Kang, Jaewon Oh, Chan Joo Lee, Sungha Park, Seok-Min Kang, Sang-Hak Lee
Format: Article
Language:English
Published: Nature Portfolio 2021-04-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-88416-z
_version_ 1818344638919999488
author Jaehyung Ha
Bom Lee
Jung Mi Park
Moonjong Kang
Jaewon Oh
Chan Joo Lee
Sungha Park
Seok-Min Kang
Sang-Hak Lee
author_facet Jaehyung Ha
Bom Lee
Jung Mi Park
Moonjong Kang
Jaewon Oh
Chan Joo Lee
Sungha Park
Seok-Min Kang
Sang-Hak Lee
author_sort Jaehyung Ha
collection DOAJ
description Abstract In this retrospective study, we investigated whether lipid-lowering therapy (LLT) escalation has clinical benefits in patients with atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol (LDL-C) levels of 55–99 mg/dL (1.4–2.6 mmol/L), post high-intensity. Out of 6317 Korean patients screened in 2005–2018, 1159 individuals with ASCVD and LDL-C levels of 55–99 mg/dL after statin use equivalent to 40 mg atorvastatin were included. After 1:2 propensity score matching, 492 patients (164 with LLT escalation, 328 controls without LLT escalation) were finally analysed. Primary outcome variables were major adverse cardiovascular and cerebrovascular events (MACCE) and all-cause death. At median follow-up (1.93 years), the escalation group had a lower MACCE rate (1.72 vs. 3.38 events/100 person-years; hazard ratio [HR] 0.34, 95% confidence interval [CI] 0.14–0.83; p = 0.018) than the control group. The incidence of all-cause death (0.86 vs. 1.02 events/100 person-years; HR 0.58, 95% CI 0.15–2.19; p = 0.42) and each MACCE component did not differ between groups. Kaplan–Meier curves exhibited lower risk of MACCE in the escalation group (HR 0.36, 95% CI 0.12–0.97; p = 0.040) but a difference not statistically significant in all-cause death (HR 0.30, 95% CI 0.04–2.48; p = 0.26). LLT escalation was associated with reduced cardiovascular risk, supporting more aggressive LLT in this population.
first_indexed 2024-12-13T16:49:40Z
format Article
id doaj.art-3a6419087aa740d3bbddc86e514189e5
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-12-13T16:49:40Z
publishDate 2021-04-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-3a6419087aa740d3bbddc86e514189e52022-12-21T23:38:04ZengNature PortfolioScientific Reports2045-23222021-04-011111810.1038/s41598-021-88416-zEscalation of liPid-lOwering therapy in patientS wiTh vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH studyJaehyung Ha0Bom Lee1Jung Mi Park2Moonjong Kang3Jaewon Oh4Chan Joo Lee5Sungha Park6Seok-Min Kang7Sang-Hak Lee8Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of MedicineDivision of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of MedicineDepartment of Biostatistics and Computing, Graduate School, Yonsei UniversityDepartment of Biostatistics and Computing, Graduate School, Yonsei UniversityDivision of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of MedicineDivision of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of MedicineDivision of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of MedicineDivision of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of MedicineDivision of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of MedicineAbstract In this retrospective study, we investigated whether lipid-lowering therapy (LLT) escalation has clinical benefits in patients with atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol (LDL-C) levels of 55–99 mg/dL (1.4–2.6 mmol/L), post high-intensity. Out of 6317 Korean patients screened in 2005–2018, 1159 individuals with ASCVD and LDL-C levels of 55–99 mg/dL after statin use equivalent to 40 mg atorvastatin were included. After 1:2 propensity score matching, 492 patients (164 with LLT escalation, 328 controls without LLT escalation) were finally analysed. Primary outcome variables were major adverse cardiovascular and cerebrovascular events (MACCE) and all-cause death. At median follow-up (1.93 years), the escalation group had a lower MACCE rate (1.72 vs. 3.38 events/100 person-years; hazard ratio [HR] 0.34, 95% confidence interval [CI] 0.14–0.83; p = 0.018) than the control group. The incidence of all-cause death (0.86 vs. 1.02 events/100 person-years; HR 0.58, 95% CI 0.15–2.19; p = 0.42) and each MACCE component did not differ between groups. Kaplan–Meier curves exhibited lower risk of MACCE in the escalation group (HR 0.36, 95% CI 0.12–0.97; p = 0.040) but a difference not statistically significant in all-cause death (HR 0.30, 95% CI 0.04–2.48; p = 0.26). LLT escalation was associated with reduced cardiovascular risk, supporting more aggressive LLT in this population.https://doi.org/10.1038/s41598-021-88416-z
spellingShingle Jaehyung Ha
Bom Lee
Jung Mi Park
Moonjong Kang
Jaewon Oh
Chan Joo Lee
Sungha Park
Seok-Min Kang
Sang-Hak Lee
Escalation of liPid-lOwering therapy in patientS wiTh vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study
Scientific Reports
title Escalation of liPid-lOwering therapy in patientS wiTh vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study
title_full Escalation of liPid-lOwering therapy in patientS wiTh vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study
title_fullStr Escalation of liPid-lOwering therapy in patientS wiTh vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study
title_full_unstemmed Escalation of liPid-lOwering therapy in patientS wiTh vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study
title_short Escalation of liPid-lOwering therapy in patientS wiTh vascular disease receiving HIGH-intensity statins: the retrospective POST-HIGH study
title_sort escalation of lipid lowering therapy in patients with vascular disease receiving high intensity statins the retrospective post high study
url https://doi.org/10.1038/s41598-021-88416-z
work_keys_str_mv AT jaehyungha escalationoflipidloweringtherapyinpatientswithvasculardiseasereceivinghighintensitystatinstheretrospectiveposthighstudy
AT bomlee escalationoflipidloweringtherapyinpatientswithvasculardiseasereceivinghighintensitystatinstheretrospectiveposthighstudy
AT jungmipark escalationoflipidloweringtherapyinpatientswithvasculardiseasereceivinghighintensitystatinstheretrospectiveposthighstudy
AT moonjongkang escalationoflipidloweringtherapyinpatientswithvasculardiseasereceivinghighintensitystatinstheretrospectiveposthighstudy
AT jaewonoh escalationoflipidloweringtherapyinpatientswithvasculardiseasereceivinghighintensitystatinstheretrospectiveposthighstudy
AT chanjoolee escalationoflipidloweringtherapyinpatientswithvasculardiseasereceivinghighintensitystatinstheretrospectiveposthighstudy
AT sunghapark escalationoflipidloweringtherapyinpatientswithvasculardiseasereceivinghighintensitystatinstheretrospectiveposthighstudy
AT seokminkang escalationoflipidloweringtherapyinpatientswithvasculardiseasereceivinghighintensitystatinstheretrospectiveposthighstudy
AT sanghaklee escalationoflipidloweringtherapyinpatientswithvasculardiseasereceivinghighintensitystatinstheretrospectiveposthighstudy